Nalbuphine hydrochloride hydrate
SIGMA/N4396 - ≥98% (HPLC)
Synonym: 17-
CAS Number: 23277-43-2 (anhydrous)
Empirical Formula (Hill Notation): C21H27NO4 · HCl · xH2O
Molecular Weight: 393.90 (anhydrous basis)
EC Number: 245-549-9
Linear Formula: C21H27NO4 · HCl · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| drug control | regulated under CDSA - not available from Sigma-Aldrich Canada |
| form | powder |
| InChI | 1S/C21H27NO4.ClH.H2O/c23- |
| InChI key | IUGXDRGXUYNFHK-XSFMULHUSA |
| originator | Abbott |
| Quality Level | 100 ![]() |
| SMILES string | Cl[H].[H]O[H].[H][C@@]12O |
| solubility | ethanol: soluble |
| H2O: soluble |
| Biochem/physiol Actions: | Partial agonist for μ and κ opioid receptors. |
| Features and Benefits: | This compound was developed by Abbott . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Nalbuphine functions as an analgesic. It has anti catabolic properties. Nalbuphine maybe associated with sedation, nausea and vomiting. |
| Packaging: | 25, 100 mg in glass bottle |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H300 + H310 + H330 |
| Precautionary statements | P260 - P262 - P264 - P280 - P302 + P352 + P310 - P304 + P340 + P310 |
| Hazard Codes | T+ |
| Risk Statements | 26/27/28 |
| Safety Statements | 22-36/37/39-45 |
| RIDADR | UN 2811 6.1 / PGII |
| WGK Germany | WGK 3 |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |


